Acquisition of Biostrand (Tables) - Biostrand BV

12 Months Ended

Apr. 30, 2026

Disclosure of detailed information about business combination [line items]

Summary of Allocated Purchase Price

The Company has allocated the purchase price as follows:


(in thousands)		$
Cash			4,985
Common shares of the Company			29,126
Fair value of consideration			34,111

Cash			36
Amounts receivable			80
Unbilled revenue			8
Equipment and right-of-use assets			247
Intellectual property (not deductible for tax purposes)			28,459
Proprietary processes (not deductible for tax purposes)			391
Goodwill (not deductible for tax purposes)			12,658
Accounts payable and accrued liabilities assumed			(342	)
Deferred revenue			9
Leases			(223	)
Deferred income tax liability			(7,212	)
			34,111

Summary of Changes in Value of Subsequent Payments

The changes in the value of the subsequent payments during the years ended April 30, 2026, 2025 and 2024 are as follows:


(in thousands)		$
Balance, April 30, 2024			285
Foreign exchange			19
Accretion			10
Balance, April 30, 2025			314
Foreign exchange			(2	)
Deferred acquisition payments			(312	)
Accretion			—
Balance, April 30, 2026			—